{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:54:13Z","timestamp":1790463253489,"version":"4.1.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,8,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A gain in chromosome 1q (+1q) is among the most common cytogenetic abnormalities in multiple myeloma (MM). It is unclear whether +1q is independently associated with decreased overall survival (OS). The objective of this study was to evaluate the impact of +1q on clinical characteristics, treatment response, and survival outcomes. We included 1376 Mayo Clinic patients diagnosed with MM from 2005 to 2018 who underwent fluorescence in situ hybridization testing at diagnosis with a panel including the +1q probe. A gain in 1q was found in 391 patients (28%) and was associated with anemia, hypercalcemia, high tumor burden, International Staging System (ISS) stage 3, high-risk (HR) translocations, and chromosome 13 abnormalities. There was no difference in overall response or deeper responses to proteasome inhibitor (PI)\u2013, immunomodulatory drug (iMiD)\u2013, or PI plus IMiD\u2013based induction. Time to next treatment was shorter in patients with +1q compared with those without +1q (19.9 vs 27.7 months; P &amp;lt; .001). On univariate analysis, +1q was associated with increased risk of death (risk ratio [RR], 1.9; P &amp;lt; .001), and decreased OS was seen in all treatment groups. +1q was independently associated with decreased OS on multivariate analysis when other HR cytogenetic abnormalities, ISS stage 3, and age \u226570 years were included (RR, 1.5; P &amp;lt; .001). Gain of &amp;gt;1 copy of 1q was not associated with worse OS compared with gain of 1 copy (4.9 vs 4.3 years; P = .21). +1q was associated with high tumor burden, advanced disease stage, and HR translocations. It is independently associated with decreased OS, even in the setting of novel therapy and transplant.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002218","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T15:34:04Z","timestamp":1596555244000},"page":"3509-3519","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":90,"title":["Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-1589","authenticated-orcid":false,"given":"Nadine","family":"Abdallah","sequence":"first","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Greipp","sequence":"additional","affiliation":[{"name":"Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda B.","family":"Baughn","sequence":"additional","affiliation":[{"name":"Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-1559","authenticated-orcid":false,"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi L.","family":"Hwa","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie","family":"Fonder","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"Division of Hematology,"},{"name":"Division of Nephrology, Department of Internal Medicine, Mayo Clinic, Rochester, MN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4640-7311","authenticated-orcid":false,"given":"Mustaqeem","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lust","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett","family":"Ketterling","sequence":"additional","affiliation":[{"name":"Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,8,4]]},"reference":[{"issue":"1","key":"2020080411332619300_B1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"2020080411332619300_B2","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"2020080411332619300_B3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas - current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"2020080411332619300_B4","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"2020080411332619300_B5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013 [published correction appears in Mayo Clin Proc. 2013;88(7):777]","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"2020080411332619300_B6","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","article-title":"Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics [published correction appears in Blood. 2014;123(10):1621]","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"2020080411332619300_B7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10245330512331390140","article-title":"Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma","volume":"10","author":"Shaughnessy","year":"2005","journal-title":"Hematology"},{"issue":"8","key":"2020080411332619300_B8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/gcc.2","article-title":"MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy","volume":"57","author":"Samo","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"2020080411332619300_B9","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood-2018-02-832576","article-title":"Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis","volume":"132","author":"Teoh","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2020080411332619300_B10","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2020080411332619300_B11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"issue":"8","key":"2020080411332619300_B12","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1080\/10428194.2016.1260126","article-title":"Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation","volume":"58","author":"Shah","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2020080411332619300_B13","first-page":"37","article-title":"Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents","author":"Giri","year":"2019","journal-title":"J Clin Oncol."},{"issue":"11","key":"2020080411332619300_B14","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","article-title":"Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma","volume":"20","author":"Fonseca","year":"2006","journal-title":"Leukemia"},{"issue":"27","key":"2020080411332619300_B15","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1200\/JCO.2008.20.6136","article-title":"Prognostic significance of copy-number alterations in multiple myeloma","volume":"27","author":"Avet-Loiseau","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020080411332619300_B16","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"issue":"15","key":"2020080411332619300_B17","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma [published correction appears in J Clin Oncol. 2005;23(25):6281]","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020080411332619300_B18","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"2020080411332619300_B19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/sj.leu.2404516","article-title":"A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy","volume":"21","author":"Stewart","year":"2007","journal-title":"Leukemia"},{"issue":"12","key":"2020080411332619300_B20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"issue":"4","key":"2020080411332619300_B21","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bbmt.2009.11.025","article-title":"Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy","volume":"16","author":"Nemec","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2020080411332619300_B22","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.bbmt.2016.09.003","article-title":"Outcome of patients with multiple myeloma and CKS1B gene amplification after autologous hematopoietic stem cell transplantation","volume":"22","author":"Bock","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"2020080411332619300_B23","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1182\/bloodadvances.2019000702","article-title":"Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting","volume":"3","author":"Slomp","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2020080411332619300_B24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2013.088211","article-title":"Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value","volume":"99","author":"An","year":"2014","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/15\/3509\/1751440\/advancesadv2020002218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/15\/3509\/1751440\/advancesadv2020002218.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T15:34:18Z","timestamp":1596555258000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/15\/3509\/461689\/Clinical-characteristics-and-treatment-outcomes-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,4]]},"references-count":24,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2020,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002218","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,4]]}}}